Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Cronos Group
CRON
Cronos Group
Regulatory Shifts In Israel And Germany Will Hinder Cannabis Growth
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
26 Aug 25
Updated
26 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$2.90
22.1% overvalued
intrinsic discount
26 Aug
CA$3.54
1Y
19.2%
7D
-0.3%
Loading
1Y
19.2%
7D
-0.3%
Author's Valuation
CA$2.9
22.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$2.9
22.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-373m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$157.3m
Earnings US$52.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.96%
Pharma revenue growth rate
0.59%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
US$52.27m
Earnings '28
x
18.34x
PE Ratio '28
=
US$958.51m
Market Cap '28
US$958.51m
Market Cap '28
/
384.88m
No. shares '28
=
US$2.49
Share Price '28
US$2.49
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
US$2.09
Fair Value '25
US$2.09
Fair Value '25
Converted to CAD @ 1.3825 USD/CAD Exchange Rate
=
CA$2.89
Fair Value '25
